Myo Myint Ohn
Follow
Get notifications in MyBN when activity occurs.
Myo Myint Ohn
Non-Executive Director / DXN
Dr Myo Myint Ohn has been the founder of several startups that have made advancements in engineering leading to new products in established and emerging markets. He is also chief executive of several startup
companies that includes Campana Group, an operator of wireline telecommunication services in South-East Asia.
Dr Ohn has also worked for large cap NASDAQ-listed companies in various roles from business unit general management, corporate strategy head to corporate M&A.
He holds an EMBA from Queens University, a PhD in Aerospace Engineering and a Master of Science in Photonics - both from University of Toronto.
companies that includes Campana Group, an operator of wireline telecommunication services in South-East Asia.
Dr Ohn has also worked for large cap NASDAQ-listed companies in various roles from business unit general management, corporate strategy head to corporate M&A.
He holds an EMBA from Queens University, a PhD in Aerospace Engineering and a Master of Science in Photonics - both from University of Toronto.
Lists and Charts
Total Shareholder Return as at 29/02/24
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 516th | Orthocell | 10% | 27% |
| 628th | Resonance Health | 3% | -7% |
| 1086th | RBR Group | -25% | -34% |
| 1194th | Adveritas | -32% | -13% |
| 1565th | DXN | -56% | -53% |
1790 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 113th |  | DXN | $6.2m |
| 119th |  | Adveritas | $5.4m |
| 120th | | RBR Group | $5.3m |
| 123rd | | Resonance Health | $4.5m |
| 124th | | Orthocell | $4.3m |
202 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Person Activity
 | NEWS: Tagged in Board Moves March 1, 2024 | 01 Mar 2024 |
| NEW ROLE: Non-Executive Director, DXN | 01 Mar 2024 |
